Altimmune Inc Share Price Nasdaq
Equities
US02155H1014
Biotechnology & Medical Research
Sales 2024 * | 31.25M 2.46B | Sales 2025 * | 25M 1.97B | Capitalization | 546M 42.95B |
---|---|---|---|---|---|
Net income 2024 * | -59M -4.64B | Net income 2025 * | -142M -11.17B | EV / Sales 2024 * | 15.4 x |
Net cash position 2024 * | 63.88M 5.03B | Net cash position 2025 * | 257M 20.19B | EV / Sales 2025 * | 11.6 x |
P/E ratio 2024 * |
-9.15
x | P/E ratio 2025 * |
-6.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 29/11/18 |
Director of Finance/CFO | 66 | 30/12/21 | |
Anthony Blandin
CMP | Compliance Officer | - | 31/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 31/03/10 |
Mack Gill
BRD | Director/Board Member | 72 | 31/07/04 |
Philip Hodges
BRD | Director/Board Member | 56 | 31/08/03 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |